US green light for Remicade biosimilar

24th April 2017 Uncategorised 0

US regulators have approved Renflexis, a biosimilar referencing Johnson & Johnson’s tumour necrosis factor (TNF) blocker Remicade (infliximab), across all eligible indications.

More: US green light for Remicade biosimilar
Source: News